top of page

FDA accepts Velicept's IND to start phase I study for solabegron

The US Food and Drug Administration (FDA) has accepted Velicept Therapeutics' Investigational New Drug (IND) application to initiate a Phase I pharmacokinetic study for a once-daily formulation for solabegron.

Solabegron is a highly potent and selective beta-3 adrenoceptor agonist that is being developed for the treatment of overactive bladder (OAB).

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page